Novartis Ag (NVS) Goodwill & Intangibles (2009 - 2026)
Novartis Ag's (NVS) quarterly Goodwill & Intangibles came in at $68.8 billion in Q2 2026, up 25.64% year-over-year from $54.8 billion in Q2 2025, and up 2.7% quarter-over-quarter from $67.0 billion in Q1 2026.
Analysis
Novartis Ag (NVS) Goodwill & Intangibles (2009 - 2026) Analysis & Trends
Novartis Ag has disclosed Goodwill & Intangibles across 18 years of filings, most recently posting $68.8 billion for Q2 2026.
- In Q2 2026, Goodwill & Intangibles rose 25.64% year-over-year to $68.8 billion; the TTM figure through Jun 2026 stood at $68.8 billion (up 25.64% YoY), while the FY2025 annual figure was $68.3 billion, up 13.42% from the prior year.
- Goodwill & Intangibles came in at $68.8 billion for Q2 2026 at Novartis Ag, up from $67.0 billion in the prior quarter.
- In the past five years, Goodwill & Intangibles ranged from a high of $68.8 billion in Q2 2026 to a low of $31.0 billion in Q1 2023.
- Average Goodwill & Intangibles over 5 years is $55.4 billion, with a median of $56.2 billion recorded in 2023.
- Year-over-year, Goodwill & Intangibles slipped 17.71% in 2023 and soared 58.97% in 2024.
- Over 5 years, Goodwill & Intangibles stood at $60.9 billion in 2022, then decreased by 4.31% to $58.3 billion in 2023, then grew by 3.24% to $60.2 billion in 2024, then climbed by 13.42% to $68.3 billion in 2025, then rose by 0.82% to $68.8 billion in 2026.
- Per Business Quant data, the three most recent Goodwill & Intangibles figures were $68.8 billion in Q2 2026, $67.0 billion in Q1 2026, and $68.3 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 68.84 Bn |
| Mar 31, 2026 | 67.03 Bn |
| Dec 31, 2025 | 68.28 Bn |
| Sep 30, 2025 | 54.59 Bn |
| Jun 30, 2025 | 54.79 Bn |
| Mar 31, 2025 | 52.44 Bn |
| Dec 31, 2024 | 60.21 Bn |
| Sep 30, 2024 | 52.83 Bn |
| Jun 30, 2024 | 53.01 Bn |
| Mar 31, 2024 | 49.34 Bn |
| Dec 31, 2023 | 58.32 Bn |
| Sep 30, 2023 | 49.83 Bn |
| Jun 30, 2023 | 57.53 Bn |
| Mar 31, 2023 | 31.03 Bn |
| Dec 31, 2022 | 60.95 Bn |
| Sep 30, 2022 | 60.56 Bn |
| Jun 30, 2022 | 62.48 Bn |
| Mar 31, 2022 | 35.00 Bn |
| Dec 31, 2021 | 63.78 Bn |
| Sep 30, 2021 | 63.52 Bn |